Renaissance Technologies's UTHR Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 1.91 M shares of United Therapeutics Corporation (UTHR) worth $930.29 M, representing 1.44% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in UTHR, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2019, adding 799,200 shares. Largest reduction occurred in Q1 2021, reducing 399,700 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -264,133 | Reduce 12.15% | 1.91 M | $487.25 |
| Q3 2025 | +54,300 | Add 2.56% | 2.17 M | $419.21 |
| Q2 2025 | +12,100 | Add 0.57% | 2.12 M | $287.35 |
| Q1 2025 | +17,600 | Add 0.84% | 2.11 M | $308.27 |
| Q4 2024 | -66,000 | Reduce 3.06% | 2.09 M | $352.84 |
| Q3 2024 | -19,300 | Reduce 0.89% | 2.16 M | $358.35 |
| Q2 2024 | +22,978 | Add 1.07% | 2.17 M | $318.55 |
| Q1 2024 | -18,500 | Reduce 0.85% | 2.15 M | $229.72 |
| Q4 2023 | -80,294 | Reduce 3.57% | 2.17 M | $219.89 |
| Q3 2023 | +63,294 | Add 2.89% | 2.25 M | $225.87 |
| Q2 2023 | -40,200 | Reduce 1.80% | 2.19 M | $0.22 |
| Q1 2023 | -117,078 | Reduce 4.99% | 2.23 M | $0.22 |
| Q4 2022 | -205,722 | Reduce 8.07% | 2.34 M | $0.28 |
| Q3 2022 | -243,377 | Reduce 8.71% | 2.55 M | $209.38 |
| Q2 2022 | +28,378 | Add 1.03% | 2.79 M | $235.64 |
| Q1 2022 | -151,978 | Reduce 5.21% | 2.77 M | $179.41 |
| Q4 2021 | -111,400 | Reduce 3.68% | 2.92 M | $216.08 |
| Q3 2021 | -81,600 | Reduce 2.62% | 3.03 M | $184.58 |
| Q2 2021 | -97,400 | Reduce 3.04% | 3.11 M | $179.41 |
| Q1 2021 | -399,700 | Reduce 11.08% | 3.21 M | $167.27 |
| Q4 2020 | -101,727 | Reduce 2.74% | 3.61 M | $151.79 |
| Q3 2020 | -17,800 | Reduce 0.48% | 3.71 M | $101.00 |
| Q2 2020 | +136,595 | Add 3.80% | 3.73 M | $121.00 |
| Q1 2020 | +45,790 | Add 1.29% | 3.59 M | $94.83 |
| Q4 2019 | +332,155 | Add 10.34% | 3.54 M | $88.08 |
| Q3 2019 | +171,300 | Add 5.63% | 3.21 M | $79.75 |
| Q2 2019 | +799,200 | Add 35.65% | 3.04 M | $78.06 |
| Q1 2019 | +45,000 | Add 2.05% | 2.24 M | $117.37 |
| Q4 2018 | +252,700 | Add 13.00% | 2.2 M | $108.90 |
| Q3 2018 | +387,878 | Add 24.92% | 1.94 M | $127.88 |
| Q2 2018 | +22,322 | Add 1.46% | 1.56 M | $113.15 |
| Q1 2018 | +71,500 | Add 4.89% | 1.53 M | $112.36 |
| Q4 2017 | +189,378 | Add 14.88% | 1.46 M | $147.95 |
| Q3 2017 | +435,400 | Add 51.98% | 1.27 M | $117.19 |
| Q2 2017 | +331,400 | Add 65.47% | 837,600 | $129.73 |
| Q1 2017 | +85,000 | Add 20.18% | 506,200 | $135.38 |
| Q4 2016 | +31,100 | Add 7.97% | 421,200 | $143.43 |
| Q3 2016 | -14,200 | Reduce 3.51% | 390,100 | $118.08 |
| Q2 2016 | -70,278 | Reduce 14.81% | 404,300 | $105.92 |
| Q1 2016 | -77,500 | Reduce 14.04% | 474,578 | $111.43 |
| Q4 2015 | -314,700 | Reduce 36.31% | 552,078 | $156.61 |
| Q3 2015 | +55,200 | Add 6.80% | 866,778 | $131.24 |
| Q2 2015 | +365,078 | Add 81.76% | 811,578 | $173.95 |
| Q1 2015 | +261,262 | Add 141.04% | 446,500 | $172.43 |
| Q4 2014 | +182,860 | Add 7689.66% | 185,238 | $129.49 |
| Q3 2014 | -250,100 | Reduce 99.06% | 2,378 | $128.68 |
| Q2 2014 | -35,462 | Reduce 12.32% | 252,478 | $88.49 |
| Q1 2014 | +63,662 | Add 28.39% | 287,940 | $94.03 |
| Q4 2013 | -216,500 | Reduce 49.12% | 224,278 | $113.08 |
| Q3 2013 | -149,600 | Reduce 25.34% | 440,778 | $78.85 |
| Q2 2013 | +590,378 | Add 0.00% | 590,378 | $65.82 |
Renaissance Technologies's United Therapeutics Corporation Investment FAQs
Renaissance Technologies first purchased United Therapeutics Corporation (UTHR) in Q2 2013, acquiring 590,378 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held United Therapeutics Corporation (UTHR) for 51 quarters since Q2 2013.
Renaissance Technologies's largest addition to United Therapeutics Corporation (UTHR) was in Q2 2019, adding 3,040,978 shares worth $237.38 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 1,909,259 shares of United Therapeutics Corporation (UTHR), valued at approximately $930.29 M.
As of the Q4 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 1.44% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in United Therapeutics Corporation (UTHR) was 3,726,818 shares, as reported at the end of Q2 2020.